Blood cancer, Cancer, primary central nervous system lymphomas
CRISCurisCatalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for CA-4948 (emavusertib)+/- ibrutinib in Blood cancer, Cancer, primary central nervous system lymphomas. The expected timing is based on the latest available company guidance and may change.
TakeAim Lymphoma study. 9/24- Initial efficacy data at IRAK4 Symposium in Cancer. 11/14/24- Ongoing discussion w/ RA to gain alignment on the registrational path. 11/6/25: Enrollment ongoing; present updated data at SNO annual meeting on November 19-23, 2025. 03/19/26:- SNO 2025 TakeAim Lymphoma data: 100% ORR in BTKi-naïve PCNSL, 37% ORR in BTKi-experienced; 1 CR SCNSL. 05/12/26:- Enrollment ongoing; updated TakeAim Lymphoma PCNSL data from emavusertib+ibrutinib expected in H1 2027. 07/22/26:- Updated PCNSL ORR 100% BTKi-naïve, 33% BTKi-experienced. H1 2027 update remains; FDA/EMA supportive.
Verification
Confirm timing and program details against the company announcement or filing.